Literature DB >> 26314433

[MiR-18a Can Regulate Chemotherapy Sensitivity of Leukemia Cell HL-60 to VP-16 and VCR by Targeting ATM].

Yue Xiao1, Rong Hu2.   

Abstract

OBJECTIVE: To investigate the regulatory effects of miR-18a on chemotherapeutic sensitivity of leukemia cell HL-60 to VP-16 and VCR, and explore its molecular mechamism.
METHODS: The HL-60 PC DNA3.1-miR-18A cell line with stably overexpressing miR-18a was constructed and their sensitivity to VP-16 and VCR was detected. The luciferase reporter vector of ATM 3'UTR region was constructed and the targeting effect of miR-18a on ATM was identified. The expression level of ATM in HL-60 cells overexpressing miR-18a was detected by Western blot. The seusitivity of HL-60 cells with knockdown of ATM to VP-16 and VCR was detected by CCK-8 method. The ATM expression level in HL-60 cells with stably overexpression miR-18a after transfection of miR-18a inhibitor was detected by using Western blot and the sensitivity changes of these HL-60 cells to VP-16 and BCR were detected.
RESULTS: After overexpression of miR-18a, the viability of HL-60 cells treated with VP-16 and VCR of same concentration decreased; the detectiion of luciferase activity showed that the miR-18a could inhitit activity of luciferase reporter vector of ATM; the expression level of ATM in HL-60 cells was down-regulated after transfection with miR-18a; the cell viability decreased when HL-60 cells were treated with VP-16 and VCR after knockdown of ATM; the expression level of ATM was up-regulated and the cell viability decreased when HL-60 cells were treated with VP-16 and VCR after transfection with miR-18a inhibitor.
CONCLUSION: The miR-18a can regulated the sensitivity of leukemia HL-60 cells to VP-16 and VCR by targeting ATM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26314433     DOI: 10.7534/j.issn.1009-2137.2015.04.017

Source DB:  PubMed          Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi        ISSN: 1009-2137


  1 in total

1.  MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer.

Authors:  Chen Liang; Xing Zhang; Hui-Min Wang; Xiao-Min Liu; Xin-Ju Zhang; Bo Zheng; Guang-Ren Qian; Zhong-Liang Ma
Journal:  Cell Death Dis       Date:  2017-05-04       Impact factor: 8.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.